BCL2 and cancer: The study reveals that cancer cells resist apoptosis through BCL-2 family deregulation, but this resistance can be overcome by combining BTSA1.2 with Navitoclax, demonstrating synergistic efficacy in resistant cancers while sparing healthy tissues, offering a novel therapeutic strategy [114, 116].